The Global Lyme Disease Diagnostic Devices Market is projected to reach $4.48 billion by 2028, from a value of $2.64 billion in 2022, by registering a CAGR of 9.2% during the forecast period. Technological advancement in the field of new diagnostic approach, rising policy attention on enhancing health care services, upsurge in incidence of lyme disease, favourable government towards healthcare facilities, and growing investment in research and development are the major factors propelling the growth of the market. However, limited awareness in lyme disease diagnostic process is hampering market growth. Moreover, growth in interests of key players toward R&D of Lyme disease diagnosis is creating ample opportunities across the globe.

Recent Developments

In July 2019, Qiagen and DiaSorin have expanded their QuantiFeron cooperation to produce an ultra-sensitive Lyme disease diagnostic test. According to the firms, the QuantiFeron-Lyme test will be used in conjunction with Liaison Borrelia IgG and IgM assays, risk assessment and other medical and diagnostic assessments, making it synergistic with DiaSorin’s Liaison IgM assays.

In July 2019, PerkinElmer has collaborated with EverlyWell for accelerating the innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer’s CLIA-certified and CAP-accredited lab facilities to EverlyWell’s network of laboratory providers. The first offerings resulting from this collaboration include the Lyme disease and food sensitivity tests for which PerkinElmer would provide the expertise behind EverlyWell’s panels.

In April 2019, Bio-Rad Laboratories Inc., a global leader in life science research and clinical diagnostic technologies, announced that its BioPlex 2200 Lyme Total Assay, a revolutionary multiplex test method to aid in the diagnosis of Lyme disease, has gained FDA clearance.

In January 2019, T2 Biosystems Inc., has launched the T2Lyme PanelTM, which is said to be more accurate than previous diagnostics in detecting Borrelia infections in patients with early Lyme disease. The T2Lyme Panel is designed to detect Lyme disease-causing bacteria in 3 to 5 hours utilizing the fully automated FDA-cleared T2Dx® Instrument.

In February 2015, Canon U.S. Life Sciences signed a strategic collaboration with T2 Biosystems, Inc., a leading manufacturer of diagnostic products to provide the patients’ well-being to develop a novel diagnostic test panel to rapidly detect Lyme disease.

Competitive Landscape

Canon U.S. Life Sciences, PerkinElmer Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, Roche Diagnostics International Ltd., Qiagen, Inc., GlaxoSmithKline Pharmaceuticals Ltd., Baxter International Inc., Siemens AG, T2 Biosystems Inc., Alere Inc (ALR), Graphene Frontiers, Fresenius Medical Care AG & Co., DiaSorin S.p.A, Thermo Fisher Scientific, Inc., Trinity Biotech plc, Quest Diagnostics, Ceres Nanosciences, Inc., Affymetrix Inc., and Immunetics Inc. are some of the major players in the global Lyme Disease Diagnostic Devices market.